APUS vs ACRS vs PRGO vs CRL

For growth investors, Charles River Laboratories International, Inc.

(CRL) is the stronger pick with -0. 9% revenue growth year-over-year, versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). Analysts rate Aclaris Therapeutics, Inc. (ACRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Apimeds Pharmaceuticals US, Inc (APUS) delivered a total return of -33.

2%, compared to -78. 8% for Aclaris Therapeutics, Inc. (ACRS). Over 10 years, the gap is even starker: CRL returned +119. 2% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.

(ACRS) is the lower-risk stock at 0. 30β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 401% more volatile than ACRS relative to the S&P 500. On balance sheet safety, Apimeds Pharmaceuticals US, Inc (APUS) carries a lower debt/equity ratio of 5% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Charles River Laboratories International, Inc.

(CRL) is pulling ahead at -0. 9% versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). On earnings-per-share growth, the picture is similar: Aclaris Therapeutics, Inc. grew EPS 69. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, CRL leads at 0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Apimeds Pharmaceuticals US, Inc (APUS) is the more profitable company, earning 0.

0% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — ACRS leads at 73. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 10. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACRS: 105. 8% to $10. 00.

In this comparison, PRGO (9.

8% yield) pays a dividend. APUS, ACRS, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Aclaris Therapeutics, Inc.

(ACRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 30)). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACRS: -76. 3%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: APUS is a small-cap quality compounder stock; ACRS is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; CRL is a small-cap quality compounder stock. PRGO pays a dividend while APUS, ACRS, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.